Chinese trade negotiators suddenly canceled a visit to meet U.S. farmers after they wrapped up trade talks in Washington this week.Marketsread more
President Trump also said he is "not looking for a partial deal" with Beijing, moving away from his suggestion last week that he would consider an "interim deal."Politicsread more
For investors taking a breather from the chaos in August, buckle up as the market is about go crazy again, Goldman Sachs warned.Marketsread more
Progress on trade talks will determine how far market will move above new highs.Trader Talk with Bob Pisaniread more
With "tariff man" President Trump waging a tariff war and Democratic candidates pushing against big international deals, free trade has become politically homeless, writes...2020 Electionsread more
Canadian trade union Unifor said roughly 4,500 of its members have been temporarily laid off because of the GM strike so far.Autosread more
Since the Cambridge Analytica scandal in March 2018, Facebook has suspended tens of thousands of apps stemming from an investigation into its developer ecosystem.Technologyread more
Uber Technologies Inc sued New York City on Friday over a new rule limiting how much time its drivers can spend in their vehicles.Transportationread more
The former top aide of retired United Auto Workers Vice President Joe Ashton, a former member of the GM's board, was charged Friday with conspiracy to commit wire fraud and...Autosread more
Stocks fell to their lows of the day on Friday on news that Chinese trade officials are cutting short their visit to the U.S.US Marketsread more
The wearables company has retained advisors to consider exploring a sale of the business.Technologyread more
A drug designed to combat seizures in children with severe epilepsy has been approved by an outside panel of advisors to the FDA, a major milestone on the way to full approval.
Epidiolex would be the first drug derived from cannabis on the U.S. market.
The panel of 13 advisors concluded that the benefit-risk profile of Epidiolex is favorable for the treatment of seizures. Earlier this week, FDA staff indicated support for the drug in light of the results of clinical trials.
Shares of U.K.-based GW Pharmaceuticals, which makes Epidiolex, were up more than 1 percent following the news.
The medicine's active ingredient cannabidiol is derived from the cannabis plant. Epidiolex does not contain THC and does not give patients any psychoactive effects. The FDA has already approved synthetic cannabinoids to alleviate the side effects of treatments such as chemotherapy.
Industry watchers expect the eventual approval of Epidiolex will encourage further research and investment into cannabis-based drugs.
The FDA is expected to issue a final decision on June 27.
— Reuters contributed to this report.